Latent Labs
Category: AI in Biotech / Drug Discovery
Frontier AI lab building generative models for programmable biology, licensing foundation models for protein and antibody design to biotech/pharma partners. Latent Labs was founded in 2023. The company is led by Simon Kohl. Based in London, United Kingdom. Team size: 11-50. Total funding raised: $50M. Latest round: Series A. Key investors include Radical Ventures, Sofinnova Partners, 8VC, Pillar VC, Kindred Capital, Isomer Capital, Flying Fish Partners, Jeff Dean (angel, Google Chief Scientist), Aidan Gomez (angel, Cohere founder), Mati Staniszewski (angel, ElevenLabs founder).
- Founded
- 2023
- Headquarters
- London, United Kingdom
- Team size
- 11-50
- Total funding
- $50M
Value proposition
Provides frontier generative AI models (Latent-X, Latent-X2, Latent-Y) that give researchers atom-level control over molecular biology — designing novel proteins, antibodies with low immunogenicity, and enabling AI-driven drug design without building an internal therapeutics pipeline.
Products and solutions
Latent-X (atom-level frontier model for de novo protein binder design), Latent-X2 (frontier model for drug-like antibodies with low immunogenicity), Latent-Y (lab-validated AI agent for drug design, research tier with free daily access + on-demand credits)
Unique value
Model-licensing / collaborative approach vs. competitors who build proprietary drug pipelines — democratizes frontier protein-design AI via web-based, no-code access for researchers worldwide.
Target customer
Biotech and pharmaceutical companies, academic and industrial protein/antibody researchers
Industries served
Biotechnology, Pharmaceuticals, Drug Discovery, Synthetic Biology
Technology advantage
Founding team co-developed DeepMind's Nobel Prize-winning AlphaFold2 and led DeepMind's protein design team; deep bench of alumni from DeepMind, Microsoft, Google, Stability AI, Exscientia, Mammoth Bio, Altos Labs, Zymergen.
How they differentiate
Unlike Xaira, Recursion, or Isomorphic Labs (which build proprietary in-house drug pipelines), Latent Labs licenses its foundation models to partners and offers free/web-based researcher access, positioning itself as an open, collaborative infrastructure layer for computational biology rather than a therapeutics developer.
Main competitors
Isomorphic Labs, Xaira Therapeutics, Chai Discovery, EvolutionaryScale
Key partnerships
AWS (multi-year strategic collaboration; AWS is Latent Labs' preferred cloud provider for AI training/inference, aimed at life-sciences customers, announced May 2025), GenScript Biotech (wet-lab partner performing high-throughput expression, purification and functional validation of AI-generated molecules for Latent-X2)
Major milestones
Feb 2025: Emerged from stealth with $50M total funding ($40M Series A), Launched Latent-X (de novo protein binder design model), Launched Latent-X2 (low-immunogenicity antibody model), Jul 2025: Launched web-based no-code AI tool for protein design, Launched Latent-Y, first lab-validated agent for drug design, with free researcher access tier.
Market positioning
Frontier AI-for-biology lab positioned as a platform/model provider rather than a drug developer, targeting broad researcher and industry adoption over proprietary pipeline value capture.
Geographic focus
Global, with hubs in London and San Francisco; competes primarily against US-based (Xaira, Chai Discovery, EvolutionaryScale) and UK-based (Isomorphic Labs) AI-biology labs.
About Simon Kohl
Ex-DeepMind Senior Research Scientist, co-developed AlphaFold2; co-led DeepMind's protein design team and set up DeepMind's wet lab at the Francis Crick Institute. PhD, Karlsruhe Institute of Technology (KIT).
Latest news about Latent Labs
More AI in Biotech / Drug Discovery companies
Official website: https://www.latentlabs.com